On May 28-29, The 10th IVD Industry Development Conference of China was successfully concluded at the Primus Hotel Nanchang International Expo City in Nanchang city. The conference attracted over 160,000 visits during the 2 days via livestreaming and onsite activities.

According to Kalorama estimates, the Romanian IVD market, serving 18.8 million residents, grew to $464 million in 2022.

According to the report of "The Developments and Trends of China's Medical Device Industry" released by Roland Berger, a world leading management consultancy, the Chinese medical device market exceeded 900 billion yuan in 2022. It is projected to exceed 2.2 trillion CNY (about 320 billion USD) by 2030, making China potentially the largest medical device market globally.

On May 8, Singlera Genomics announced that its self-developed PDACatch test, a novel DNA methylation-based liquid biopsy test for detecting pancreatic cancer in high-risk populations, has been granted Breakthrough Medical Device designation by FDA.

Sansure Biotech announced that the company will invest CNY 90.93 million, accounting for 53.2% of the shares, and jointly establish Hunan Sansure Ansai Biotechnology.

The 3rd Key Raw Material & Parts Forum of China is scheduled to be held at Primus Hotel Nanchang International Expo City on 28 May in 2023.

The 5th IVD Distribution Enterprise Forum of China is scheduled to be held at Primus Hotel Nanchang International Expo City on 26 May in 2023.

Following the announcement by China’s foreign ministry that PCR test results will no longer be required for all inbound travelers from April 29 onwards, the highly anticipated CACLP 2023 has entered its final countdown with less than one month to go.

On April 27, Mindray released its annual report, showing that in 2022, it achieved revenue of 30.366 billion CNY, up 20.17% year-on-year, net profit attributable to shareholders of the listed company was 9.607 billion CNY, up 20.07% year-on-year; net cash flow from operating activities was 12.141 billion CNY, up 34.92% year-on-year, and basic earnings per share was 7.94 CNY.

OpGen announced on Tuesday that it has entered into a distribution partnership for its Unyvero A50 system and in vitro diagnostic tests with Fisher Healthcare, a division of Thermo Fisher Scientific.